Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients

Liu, Can; Zhou, Nan; Li, Jieying; Kong, Jun Suk; Xi, Guan; Wang, Xudong

doi:10.1155/2017/2176460

Cited by 20 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the ndings of the present study provide a rationale for the clinical development of speci c Eg5 inhibitors for HCC treatment. Our ndings regarding the prognostic value of Eg5 expression are generally consistent with those of a previous study [24], although that study did not analyze DFS and used immunohistochemical staining, rather than quanti ed RNA expression, to evaluate tumor Eg5 expression levels.…”

Section: Discussionsupporting

confidence: 88%

Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Shao

Sun

Jeng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The kinesin Eg5, a mitosis-associated protein, is overexpressed in many cancers. Here we explored the clinical significance of Eg5 in HCC.Methods: HCC tissues from surgical resection were collected. Total RNA was prepared from tumorous and nontumorous parts. Eg5 expression levels were correlated with overall survival (OS) and disease-free survival (DFS). In vitro efficacy of LGI-147, a specific Eg5 inhibitor, was tested in HCC cell lines. In vivo efficacy of Eg5 inhibition was investigated in a xenograft model.Results: A total of 108 HCC samples were included. The patients were divided into three tertile groups with high, medium, and low Eg5 expression levels. OS of patients with low Eg5 expression was better than that of patients with medium and high Eg5 expression (median, 155.6 vs. 75.3 vs. 57.7 months, p = 0.002). DFS of patients with low Eg5 expression was also better than that of patients with medium and high Eg5 expression (median, 126.3 vs. 46.2 vs. 39.4 months, p = 0.001). In multivariate analyses, the associations between Eg5 expression and OS (p < 0.001) or DFS remained (p < 0.001). LGI-147 reduced cell growth via cell cycle arrest and apoptosis and induced accumulation of abnormal mitotic cells. In the xenograft model, the tumor growth rate under LGI-147 treatment was significantly slower than the control.Conclusion: High Eg5 expression was associated with poor HCC prognosis. In vitro and in vivo evidence suggests that Eg5 may be a reasonable therapeutic target for HCC.

show abstract

Section: Discussionsupporting

confidence: 88%

Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Shao

Sun

Jeng

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, KIF-speci c inhibitors allegedly prevent the growth and self-renewal of glioblastoma tumor stem cells [49]. Additionally, KIF11 is highly expressed in HCC and is associated with liver cirrhosis and TNM staging and can be used as a poor prognostic biomarker [50]. We demonstrate here that the high expression of KIF11 in HCC tissues is linked to negative OS, negative RFS, and negative PFS.…”

Section: Discussionmentioning

confidence: 70%

Analysis of KIF2C, 4A, 10, 11, 14, 18B, 20A, and 23 in HCC and their clinical significance as new-born prognostic markers of HCC

Qiu

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. However, the molecular mechanism of its pathogenesis remains to be studied. This study aimed to identify potential KIF genes associated with HCC progression. Methods: We used bioinformatics to initially analyze the expression level and prognostic significance of KIF factors in HCC. Results: We found that compared with the normal control group, KIF2C, 4A, 10, 11, 14, 18B, 20A, and 23 mRNA expression levels increased significantly in HCC. 8 KIF factors had different levels of gene amplification, depth to delete, and missense mutation, and were closely related to the clinical-pathologic stage. Gene set enrichment analysis showed that high mRNA expression of 8 KIF factors in HCC patients were associated with cell cycle, mismatch repair, homologous recombination, and DNA replication. Conclusions: This study expands our understanding of KIF factors in HCC and can provide a theoretical basis for further basic and clinical research in HCC.

show abstract

“…Then, quantitative PCR was performed using the SYBR MasterMix (4913850001, Roche, Basel, Switzerland), ABI 7900HT, according to the manufacturer's instructions, and then the difference was calculated using the 2 – ΔΔ CT . KIF11 primer is as follows: forward 5′-GAA CAATCATTAGCAGCAGAA-3′ and reverse 5′-TCAGTATAGACA CCACAGTTG-3′ [ 27 ]. β -Actin primer is as follows: forward primer 5′-TAATCTTCGCCTTAA TACTT-3′ and reverse primer 5′-AGCCTTCATACATCTCAA-3′ [ 27 ].…”

Section: Methodsmentioning

confidence: 99%

“…KIF11 is broadly expressed in lymph node, bone marrow, and other normal tissues. Recent researches reported that KIF11 was overexpressed in several tumors and associated with the poor prognosis, such as prostate cancer [ 22 ], gastric cancer [ 23 ], non-small cell lung cancer [ 24 ], oral cancer [ 25 ], meningioma [ 26 ], hepatic carcinoma [ 27 ], and pancreatic tumor [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers

Jiang

Sun

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) lacks effective treatments and has a poor prognosis. Therefore it is needed to develop more effective drug targets. Kinesin family member 11 (KIF11) has been reported to affect the progression of several cancers, and its high expression associates with the prognosis of patients. However, the relevant mechanisms of KIF11 in HCC progression have not been studied. Method. Through the cancer genome atlas (TCGA) database and immunohistochemical (IHC) staining of patients’ specimens, we determined that KIF11 was highly expressed in HCC tissues and associated with prognosis. We established a KIF11 stably depleted hepatoma cell line, through cell-cloning experiments and cell counting kit-8 (CCK-8) assays to detect the effects on proliferation in vitro. The role of KIF11 in promoting cell proliferation was verified in mice. Result. The expression of KIF11 was negatively correlated with the overall survival (OS) and disease-free survival (DFS) and positively correlated with tumor size of HCC patients. KIF11 depletion inhibits cell proliferation and tumor growth in vitro and in vivo. Conclusion. KIF11 can be used as a positive correlation marker for HCC prognosis and served as a potential therapeutic target.

show abstract

Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients

Cited by 20 publications

References 35 publications

Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Analysis of KIF2C, 4A, 10, 11, 14, 18B, 20A, and 23 in HCC and their clinical significance as new-born prognostic markers of HCC

KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers

Contact Info

Product

Resources

About